138 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
copies of all of the proxy materials, as well as providing access to those proxy materials on a publicly accessible website. This Proxy Statement … or on your proxy card. The meeting will begin promptly at 11:00 a.m., Eastern Time on Wednesday, May 29, 2024. We encourage you to access the meeting prior
8-K
EX-99.2
ln1199i4b86 723ls
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
k5oy1
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
tygro5hr 798
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
k27oi80dfkk8l0m
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.2
idbo236r24 qnaawhc8
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
1nsvqzbzvd flg
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
orrij6prvmc 9uwrl
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
w3tn9jf8afhff35m4fy
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
p95 v4wfz
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
62d8 9lbdudll
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm